Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

@article{Zhu2010PharmacokineticsAS,
  title={Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals},
  author={Li Zhu and Joan R. Butterton and Anna Asplund Persson and Michele Stonier and Wendy Comisar and Deborah L. Panebianco and Sheila A. Breidinger and Jenny Zhang and Richard J. Bertz},
  journal={Antiviral Therapy},
  year={2010},
  volume={15},
  pages={1107 - 1114}
}
Background Atazanavir plus raltegravir 300/400 mg twice daily is being explored as a ritonavir- and nucleoside- sparing treatment strategy. The pharmaco-kinetics and safety of this combination in healthy individuals were evaluated. Methods A total of 22 healthy individuals received raltegravir 400 mg on days 1–5, atazanavir 300 mg on days 6–12 and atazanavir plus raltegravir 300/400 mg on days 13–26, twice daily with a light meal. Serial blood samples were collected 12 h after the morning dose… 

Figures and Tables from this paper

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

  • L. MarinaroA. Calcagno S. Bonora
  • Medicine
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2017

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

In virologically suppressed adults, regimens comprising ATV plus RAL were efficacious and safe and lower than ritonavir-boosted atazanavir q24h; RAL q 24h troughs were lower than q12h; HIV RNA remained undetectable.

Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

The efficacy and safety of RAL plus ATV maintenance dual therapy demonstrated on a 3-year follow-up seemed to be appropriate, regarding the targeted levels achieved and the lack of grade 3 or 4 hyperbilirubinemia.

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial

Darunavir Ctrough and AUC were significantly lower in the pentatherapy arm than in the tritherapy arm, and a specific pharmacokinetic interaction study is needed to explore the interactions between dar unavir and maraviroc and raltegravir.

Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals

Characterizing raltegravir population pharmacokinetics in HIV-positive and healthy individuals, identify influential factors, and search for new candidate genes involved in UDP glucuronosyltransferase (UGT)-mediated glucuronidation found UGT1A9*3 was the only genetic variant possibly influencing RAL pharmacokinetic variability.

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice

Emerging RAL-resistance and discontinuations for adverse events resulted in moderate efficacy rates of ATV and RAL dual therapy in heavily pretreated patients.

Clinical Pharmacology Profile of Raltegravir, an HIV‐1 Integrase Strand Transfer Inhibitor

Raltegravir demonstrates favorable clinical pharmacology and a drug interaction profile that permits administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment.

Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.

Due to the absence of a clinically significant drug interaction, raltegravir can be recommended for combined HIV/HCV treatment including boceprevir.

Drug‐Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects

Coadministration of tropifexor with either ATZ, itraconazole, or rifampin was well tolerated and no expected drug‐drug interactions based on UGT1A1 inhibition were expected.

References

SHOWING 1-10 OF 26 REFERENCES

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

A single supratherapeutic dose design may be appropriate for crossover thorough QTc studies, after a double‐blind, randomized, placebo‐controlled, double‐dummy, 3‐period, single‐dose crossover study conducted.

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients

These findings demonstrate the safety and efficacy of the ATV300/RTV regimen and confirm the efficacy of ATV400 in an ARV-naive patient population.

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

The data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation, which is similar to that demonstrated in rats.

Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials

Evaluating lipid profiles in untreated patients found Atazanavir does not lead to dyslipidemia in ARV-naive patients, and may limit the need for lipid-lowering strategies to reduce the risk of cardiovascular disease.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

  • M. IwamotoL. Wenning J. Wagner
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

An ‘in-house’ analysis is conducted, comparing atazanavir, lopinavir and saquinavir between HIV-infected patients and healthy volunteers enrolled in the same study centre with similar study designs, focusing on protease inhibitors.

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Tenofovir-associated ARF manifests as acute tubular necrosis that may not resolve with ten ofovir withdrawal that is associated with multiple drug interactions, leading to an increased risk of ARF.